Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileScott A. Armstrong, M.D.,Ph.D.

TitleDavid G. Nathan Professor of Pediatrics
InstitutionDana-Farber Cancer Institute
DepartmentPediatrics
AddressDana-Farber Cancer Institute
Pediatric Oncology, Dana, 1641
450 Brookline Ave
Boston MA 02215
Phone617/632-3644
Fax617/632-4367
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects
Histone Deacetylase Inhibiors Induce the Expression of the Pro-Apoptotic Proetin Bim in Human MLL-rearranged Leukemia Cells
Summer, 06/27/05 - 08/19/05

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
R01CA204639     (ALLIS, CHARLES DAVID)Mar 4, 2016 - Feb 28, 2021
NIH/NCI
Functional and Mechanistic Study of Histone Crotonylation in Hematological Malignancies
Role: Co-Principal Investigator

R01CA176745     (ARMSTRONG, SCOTT A)Sep 25, 2012 - Jul 31, 2017
NIH/NCI
Targeting to Epigenetic Modications in ALL
Role: Principal Investigator

R01CA140575     (ARMSTRONG, SCOTT A)Mar 1, 2010 - Jan 31, 2016
NIH/NCI
Molecular pathogenesis of MLL-AF4 leukemias
Role: Principal Investigator

RC2CA148222     (ARMSTRONG, SCOTT A)Sep 30, 2009 - Aug 31, 2011
NIH/NCI
Comprehensive Phenotypic Comparison of Normal and Cancer Stem Cells
Role: Principal Investigator

K08CA092551     (ARMSTRONG, SCOTT A)Jul 3, 2001 - Dec 31, 2006
NIH/NCI
MLL Gene Regulation in Hematopoiesis and Leukemia
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodríguez-Fos E, Gonzalez S, Puiggròs M, Blackford AN, Mason CE, de Stanchina E, Gönen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, Kentsis A. PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet. 2017 Jul; 49(7):1005-1014. PMID: 28504702.
    View in: PubMed
  2. Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, Kwon JA, Meydan C, Perales-Paton J, Arshi A, Gönen M, Famulare C, Patel M, Paietta E, Tallman MS, Lu Y, Glass J, Garret-Bakelman FE, Melnick A, Levine R, Al-Shahrour F, Järås M, Hacohen N, Hwang A, Garippa R, Lengner CJ, Armstrong SA, Cerchietti L, Cowley GS, Root D, Doench J, Leslie C, Ebert BL, Kharas MG. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017 Jun; 49(6):866-875. PMID: 28436985.
    View in: PubMed
  3. Remillard D, Buckley DL, Paulk J, Brien GL, Sonnett M, Seo HS, Dastjerdi S, Wühr M, Dhe-Paganon S, Armstrong SA, Bradner JE. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angew Chem Int Ed Engl. 2017 May 15; 56(21):5738-5743. PMID: 28418626.
    View in: PubMed
  4. Ajore R, Raiser D, McConkey M, Jöud M, Boidol B, Mar B, Saksena G, Weinstock DM, Armstrong S, Ellis SR, Ebert BL, Nilsson B. Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med. 2017 Apr; 9(4):498-507. PMID: 28264936.
    View in: PubMed
  5. Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, Wang X, Pietras EM, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017 04 06; 544(7648):53-58. PMID: 28355185.
    View in: PubMed
  6. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 Mar 24; 355(6331):1324-1330. PMID: 28336670.
    View in: PubMed
  7. Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, Souza AL, Bradner JE, Shen L, Li W, Li H, Allis CD, Armstrong SA, Shi X. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. 2017 03 09; 543(7644):265-269. PMID: 28241141.
    View in: PubMed
  8. Krivtsov AV, Hoshii T, Armstrong SA. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harb Perspect Med. 2017 Feb 27. PMID: 28242784.
    View in: PubMed
  9. Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res. 2017 Apr 01; 77(7):1753-1762. PMID: 28202522.
    View in: PubMed
  10. Xu H, Valerio DG, Eisold ME, Sinha A, Koche RP, Hu W, Chen CW, Chu SH, Brien GL, Park CY, Hsieh JJ, Ernst P, Armstrong SA. NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. Cancer Cell. 2016 Dec 12; 30(6):863-878. PMID: 27889185.
    View in: PubMed
  11. Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016 Dec; 22(12):1488-1495. PMID: 27841873.
    View in: PubMed
  12. Valerio DG, Xu H, Eisold ME, Woolthuis CM, Pandita TK, Armstrong SA. Histone acetyltransferase activity of MOF is required for adult but not early fetal hematopoiesis in mice. Blood. 2017 Jan 05; 129(1):48-59. PMID: 27827827.
    View in: PubMed
  13. Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C. Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N terminus. Blood. 2017 Jan 19; 129(3):319-323. PMID: 27827825.
    View in: PubMed
  14. Corson AE, Armstrong SA, Wright ME, McClelland EE, Bicker KL. Discovery and Characterization of a Peptoid with Antifungal Activity against Cryptococcus neoformans. ACS Med Chem Lett. 2016 Dec 08; 7(12):1139-1144. PMID: 27994753.
    View in: PubMed
  15. Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL. AACR Cancer Progress Report 2016. Clin Cancer Res. 2016 Oct 01; 22(19 Supplement):S1-S137. PMID: 27697776.
    View in: PubMed
  16. Morgado-Palacin I, Day A, Murga M, Lafarga V, Anton ME, Tubbs A, Chen HT, Ergan A, Anderson R, Bhandoola A, Pike KG, Barlaam B, Cadogan E, Wang X, Pierce AJ, Hubbard C, Armstrong SA, Nussenzweig A, Fernandez-Capetillo O. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci Signal. 2016 Sep 13; 9(445):ra91. PMID: 27625305.
    View in: PubMed
  17. Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, Cusan M, Farnoud N, Mupo A, Grove C, Koche R, Bradner JE, de Stanchina E, Vassiliou GS, Hoshii T, Armstrong SA. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 2016 Oct; 6(10):1166-1181. PMID: 27535106.
    View in: PubMed
  18. Henssen AG, Jiang E, Zhuang J, Pinello L, Socci ND, Koche R, Gonen M, Villasante CM, Armstrong SA, Bauer DE, Weng Z, Kentsis A. Forward genetic screen of human transposase genomic rearrangements. BMC Genomics. 2016 Aug 04; 17:548. PMID: 27491780; PMCID: PMC4973553.
  19. Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia. 2017 Jan; 31(1):151-158. PMID: 27363283.
    View in: PubMed
  20. LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nat Med. 2016 Jun 07; 22(6):578-9. PMID: 27270773.
    View in: PubMed
  21. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 Jun 07; 22(6):692. PMID: 27270779.
    View in: PubMed
  22. Wang X, Chen CW, Armstrong SA. The role of DOT1L in the maintenance of leukemia gene expression. Curr Opin Genet Dev. 2016 Feb; 36:68-72. PMID: 27151433.
    View in: PubMed
  23. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, Durham BH, Yoshimi A, Kim YJ, Thomas M, Lobry C, Chen CW, Pastore A, Taylor J, Wang X, Krivtsov A, Armstrong SA, Palacino J, Buonamici S, Smith PG, Bradley RK, Abdel-Wahab O. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 Jun; 22(6):672-8. PMID: 27135740; PMCID: PMC4899191 [Available on 11/02/16].
  24. Brien GL, Valerio DG, Armstrong SA. Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell. 2016 Apr 11; 29(4):464-76. PMID: 27070701; PMCID: PMC4889129 [Available on 04/11/17].
  25. He J, Abdel-Wahab O, Nahas MK, Wang K, Rampal RK, Intlekofer AM, Patel J, Krivstov A, Frampton GM, Young LE, Zhong S, Bailey M, White JR, Roels S, Deffenbaugh J, Fichtenholtz A, Brennan T, Rosenzweig M, Pelak K, Knapp KM, Brennan KW, Donahue AL, Young G, Garcia L, Beckstrom ST, Zhao M, White E, Banning V, Buell J, Iwanik K, Ross JS, Morosini D, Younes A, Hanash AM, Paietta E, Roberts K, Mullighan C, Dogan A, Armstrong SA, Mughal T, Vergilio JA, Labrecque E, Erlich R, Vietz C, Yelensky R, Stephens PJ, Miller VA, van den Brink MR, Otto GA, Lipson D, Levine RL. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016 Jun 16; 127(24):3004-14. PMID: 26966091; PMCID: PMC4968346.
  26. Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016 Apr 01; 126(4):1438-50. PMID: 26927674; PMCID: PMC4811120.
  27. Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Rep. 2016 Mar 01; 14(8):1953-65. PMID: 26904942; PMCID: PMC4790111.
  28. Zhu N, Chen M, Eng R, DeJong J, Sinha AU, Rahnamay NF, Koche R, Al-Shahrour F, Minehart JC, Chen CW, Deshpande AJ, Xu H, Chu SH, Ebert BL, Roeder RG, Armstrong SA. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest. 2016 Mar 01; 126(3):997-1011. PMID: 26878175; PMCID: PMC4767347.
  29. Armstrong SA, Rape M. Editorial overview: Differentiation and disease. Curr Opin Cell Biol. 2015 Dec; 37:v-vi. PMID: 26626586.
    View in: PubMed
  30. Cai SF, Chen CW, Armstrong SA. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Mol Cell. 2015 Nov 19; 60(4):561-70. PMID: 26590715; PMCID: PMC4701197 [Available on 11/19/16].
  31. Brien GL, Healy E, Jerman E, Conway E, Fadda E, O'Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A, McDade SS, Martin SJ, McLysaght A, O'Connell DJ, Armstrong SA, Bracken AP. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes Dev. 2015 Nov 01; 29(21):2231-43. PMID: 26494712; PMCID: PMC4647557.
  32. Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia. 2016 May; 30(5):1220-5. PMID: 26487272; PMCID: PMC4840097 [Available on 05/01/17].
  33. Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, Shi Y, Armstrong SA, Roeder RG. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev. 2015 Oct 15; 29(20):2123-39. PMID: 26494788; PMCID: PMC4617977 [Available on 04/15/16].
  34. Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015 Nov 26; 126(22):2479-83. PMID: 26443624; PMCID: PMC4661170 [Available on 11/26/16].
  35. LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015 Nov; 21(11):1344-9. PMID: 26437366; PMCID: PMC4636469.
  36. Chen S, Yang Z, Wilkinson AW, Deshpande AJ, Sidoli S, Krajewski K, Strahl BD, Garcia BA, Armstrong SA, Patel DJ, Gozani O. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. Mol Cell. 2015 Oct 15; 60(2):319-27. PMID: 26439302; PMCID: PMC4609290 [Available on 10/15/16].
  37. Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, Caruso BT, Arefolov A, Fadeyi O, Christie AL, Du K, Banka D, Schneider EV, Jestel A, Zou G, Si C, Ebmeier CC, Bronson RT, Krivtsov AV, Myers AG, Kohl NE, Kung AL, Armstrong SA, Lemieux ME, Taatjes DJ, Shair MD. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015 Oct 08; 526(7572):273-6. PMID: 26416749; PMCID: PMC4641525.
  38. Ye M, Zhang H, Yang H, Koche R, Staber PB, Cusan M, Levantini E, Welner RS, Bach CS, Zhang J, Krivtsov AV, Armstrong SA, Tenen DG. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell. 2015 Nov 05; 17(5):611-23. PMID: 26412561; PMCID: PMC4636971 [Available on 11/05/16].
  39. Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. Exp Hematol. 2015 Nov; 43(11):930-935.e6. PMID: 26118502; PMCID: PMC4630114 [Available on 11/01/16].
  40. Chen CW, Armstrong SA. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015 Aug; 43(8):673-84. PMID: 26118503; PMCID: PMC4540610.
  41. Kühn MW, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015 Apr 13; 27(4):431-3. PMID: 25873167.
    View in: PubMed
  42. Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43. PMID: 25822366; PMCID: PMC4390532.
  43. Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res. 2015 May 15; 21(10):2348-58. PMID: 25688158; PMCID: PMC4433811.
  44. Kühn MW, Hadler MJ, Daigle SR, Koche RP, Krivtsov AV, Olhava EJ, Caligiuri MA, Huang G, Bradner JE, Pollock RM, Armstrong SA. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 2015 May; 100(5):e190-3. PMID: 25596271; PMCID: PMC4420229.
  45. Heidel FH, Arreba-Tutusaus P, Armstrong SA, Fischer T. Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia's genetic diversity. Clin Cancer Res. 2015 Jan 15; 21(2):240-8. PMID: 25593343.
    View in: PubMed
  46. Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol. 2015 Mar 20; 10(3):667-74. PMID: 25397901; PMCID: PMC4504433.
  47. Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell. 2014 Dec 04; 15(6):775-90. PMID: 25479751; PMCID: PMC4317339.
  48. Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014 Dec 16; 111(50):E5401-10. PMID: 25516983; PMCID: PMC4273376.
  49. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 08; 26(6):896-908. PMID: 25464900; PMCID: PMC4291116.
  50. Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, Aoyama S, Okamoto M, Harrington W, Gelfand E, Green TM, Tomko MJ, Gopal S, Wong TC, Li H, Howell S, Stransky N, Liefeld T, Jang D, Bistline J, Meyers BH, Armstrong SA, Anderson KC, Stegmaier K, Reich M, Pellman D, Boehm JS, Mesirov JP, Golub TR, Root DE, Hahn WC. Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044. PMID: 25982629; PMCID: PMC4411007.
  51. Deng BH, Kinley JS, Knapp K, Feng P, Martinez R, Weixel C, Armstrong S, Hayashi R, Longman A, Mendoza R, Gota H, Tuszewski M. Far infrared laser polarimetry and far forward scattering diagnostics for the C-2 field reversed configuration plasmas. Rev Sci Instrum. 2014 Nov; 85(11):11D401. PMID: 25430164.
    View in: PubMed
  52. Roche T, Sun X, Armstrong S, Knapp K, Slepchenkov M. Langmuir probe diagnostic suite in the C-2 field-reversed configuration. Rev Sci Instrum. 2014 Nov; 85(11):11D824. PMID: 25430237.
    View in: PubMed
  53. Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, Aoyama S, Okamoto M, Harrington W, Gelfand E, Green TM, Tomko MJ, Gopal S, Wong TC, Wong TC, Li H, Howell S, Stransky N, Liefeld T, Jang D, Bistline J, Hill Meyers B, Armstrong SA, Anderson KC, Stegmaier K, Reich M, Pellman D, Boehm JS, Mesirov JP, Golub TR, Root DE, Hahn WC. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035. PMID: 25984343; PMCID: PMC4432652.
  54. Lee D, Sykes SM, Kalaitzidis D, Lane AA, Kfoury Y, Raaijmakers MH, Wang YH, Armstrong SA, Scadden DT. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40. PMID: 25418727; PMCID: PMC4235746.
  55. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. PMID: 25128497; PMCID: PMC4197965.
  56. Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, Rossi DJ, Ito K, Ge K, Aplan PD, Armstrong SA, Nussenzweig A. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 2014 Oct 02; 514(7520):107-11. PMID: 25079327; PMCID: PMC4410707.
  57. Hanoun M, Zhang D, Mizoguchi T, Pinho S, Pierce H, Kunisaki Y, Lacombe J, Armstrong SA, Dührsen U, Frenette PS. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche. Cell Stem Cell. 2014 Sep 04; 15(3):365-75. PMID: 25017722; PMCID: PMC4156919.
  58. Spong J, Kennedy GA, Tseng J, Brown DJ, Armstrong S, Berlowitz DJ. Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3?mg melatonin. Spinal Cord. 2014 Aug; 52(8):629-34. PMID: 24891007.
    View in: PubMed
  59. Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Krämer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Fröhling S. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23. PMID: 24764564; PMCID: PMC4190617.
  60. Koche RP, Armstrong SA. Genomic dark matter sheds light on EVI1-driven leukemia. Cancer Cell. 2014 Apr 14; 25(4):407-8. PMID: 24735919; PMCID: PMC4046890.
  61. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469. PMID: 24662245; PMCID: PMC4016990.
  62. Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, Baylin SB, Liu XS, Schweizer L. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014 Feb; 1309:30-6. PMID: 24571255.
    View in: PubMed
  63. Chu SH, Armstrong SA. Stem cells: Dual response to Ras mutation. Nature. 2013 Dec 05; 504(7478):91-2. PMID: 24284623.
    View in: PubMed
  64. Ng CE, Sinha A, Krivtsov A, Dias S, Chang J, Armstrong SA, Kalaitzidis D. KRas(G12D)-evoked leukemogenesis does not require ß-catenin. Leukemia. 2014 Mar; 28(3):698-702. PMID: 24189294; PMCID: PMC4367949.
  65. Altschuler GM, Hofmann O, Kalatskaya I, Payne R, Ho Sui SJ, Saxena U, Krivtsov AV, Armstrong SA, Cai T, Stein L, Hide WA. Pathprinting: An integrative approach to understand the functional basis of disease. Genome Med. 2013; 5(7):68. PMID: 23890051; PMCID: PMC3971351.
  66. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013 Jul 08; 24(1):45-58. PMID: 23770013; PMCID: PMC3746037.
  67. Neff T, Armstrong SA. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013 Jun 13; 121(24):4847-53. PMID: 23649466; PMCID: PMC3682337.
  68. Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood. 2013 May 02; 121(18):3692-702. PMID: 23487027; PMCID: PMC3643767.
  69. Ho LL, Sinha A, Verzi M, Bernt KM, Armstrong SA, Shivdasani RA. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol. 2013 May; 33(9):1735-45. PMID: 23428873; PMCID: PMC3624170.
  70. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013 Mar 28; 121(13):2533-41. PMID: 23361907; PMCID: PMC3612861.
  71. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY, Aifantis I. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013 Feb 11; 210(2):301-19. PMID: 23359070; PMCID: PMC3570103.
  72. Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Döhner K, Vasioukhin V, Fischer T, Armstrong SA. The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med. 2013 Jan 14; 210(1):15-22. PMID: 23277453; PMCID: PMC3549713.
  73. Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013 Apr; 27(4):852-60. PMID: 23235717; PMCID: PMC4693300.
  74. Krivtsov AV, Armstrong SA. Cancer. Can one cell influence cancer heterogeneity? Science. 2012 Nov 23; 338(6110):1035-6. PMID: 23180850.
    View in: PubMed
  75. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr; 27(4):813-22. PMID: 23138183; PMCID: PMC3932800.
  76. Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012 Sep 07; 11(3):429-39. PMID: 22958934; PMCID: PMC3743253.
  77. Deshpande AJ, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 2012 Nov; 33(11):563-70. PMID: 22867873; PMCID: PMC4034385.
  78. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012 Jun 14; 119(24):5838-49. PMID: 22553314; PMCID: PMC3382941.
  79. Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and pharmacologic inhibition of ß-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012 Apr 06; 10(4):412-24. PMID: 22482506; PMCID: PMC3339412.
  80. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012 Mar 27; 109(13):5028-33. PMID: 22396593; PMCID: PMC3324004.
  81. Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 04; 483(7391):598-602. PMID: 22388813; PMCID: PMC3501145.
  82. Mar BG, Bullinger L, Basu E, Schlis K, Silverman LB, Döhner K, Armstrong SA. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 2012 Aug; 26(8):1881-3. PMID: 22377896; PMCID: PMC4701195.
  83. Sinha AU, Armstrong SA. iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS One. 2012; 7(2):e31690. PMID: 22393367; PMCID: PMC3290527.
  84. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012 Feb 15; 26(4):344-9. PMID: 22345515; PMCID: PMC3289882.
  85. Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011 Dec; 3(6):667-70. PMID: 22126283.
    View in: PubMed
  86. Ho Sui SJ, Begley K, Reilly D, Chapman B, McGovern R, Rocca-Sera P, Maguire E, Altschuler GM, Hansen TA, Sompallae R, Krivtsov A, Shivdasani RA, Armstrong SA, Culhane AC, Correll M, Sansone SA, Hofmann O, Hide W. The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res. 2012 Jan; 40(Database issue):D984-91. PMID: 22121217; PMCID: PMC3245064.
  87. Sinha AU, Merrill E, Armstrong SA, Clark TW, Das S. eXframe: reusable framework for storage, analysis and visualization of genomics experiments. BMC Bioinformatics. 2011 Nov 21; 12:452. PMID: 22103807; PMCID: PMC3235155.
  88. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Schöll C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011 Sep 02; 146(5):697-708. PMID: 21884932; PMCID: PMC3826540.
  89. Heidel FH, Mar BG, Armstrong SA. Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol. 2011 Aug; 94(2):109-17. PMID: 21800073; PMCID: PMC3339405.
  90. Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011 Sep 08; 118(10):2849-56. PMID: 21765021; PMCID: PMC3172801.
  91. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12; 20(1):53-65. PMID: 21741596; PMCID: PMC4046888.
  92. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12; 20(1):66-78. PMID: 21741597; PMCID: PMC3329803.
  93. Deshpande AJ, Rouhi A, Lin Y, Stadler C, Greif PA, Arseni N, Opatz S, Quintanilla-Fend L, Holzmann K, Hiddemann W, Döhner K, Döhner H, Xu G, Armstrong SA, Bohlander SK, Buske C. The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia. 2011 Nov; 25(11):1718-27. PMID: 21681188.
    View in: PubMed
  94. Kalaitzidis D, Armstrong SA. Cancer: The flipside of Notch. Nature. 2011 May 12; 473(7346):159-60. PMID: 21562551.
    View in: PubMed
  95. Zimmer SN, Zhou Q, Zhou T, Cheng Z, Abboud-Werner SL, Horn D, Lecocke M, White R, Krivtsov AV, Armstrong SA, Kung AL, Livingston DM, Rebel VI. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood. 2011 Jul 07; 118(1):69-79. PMID: 21555743; PMCID: PMC3139388.
  96. Kvinlaug BT, Chan WI, Bullinger L, Ramaswami M, Sears C, Foster D, Lazic SE, Okabe R, Benner A, Lee BH, De Silva I, Valk PJ, Delwel R, Armstrong SA, Döhner H, Gilliland DG, Huntly BJ. Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res. 2011 Jun 15; 71(12):4117-29. PMID: 21505102; PMCID: PMC3119437.
  97. Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program. 2011; 2011:354-60. PMID: 22160057.
    View in: PubMed
  98. Shannon K, Armstrong SA. Genetics, epigenetics, and leukemia. N Engl J Med. 2010 Dec 16; 363(25):2460-1. PMID: 21067376; PMCID: PMC4117480.
  99. Claus R, Plass C, Armstrong SA, Bullinger L. DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol. 2010 Sep; 6(9):1415-31. PMID: 20919827.
    View in: PubMed
  100. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010 Mar 26; 327(5973):1650-3. PMID: 20339075; PMCID: PMC3084586.
  101. Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 2010 Apr 01; 16(7):2122-30. PMID: 20332322; PMCID: PMC2920144.
  102. Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA, Lodish HF. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle. 2010 Mar 15; 9(6):1037-42. PMID: 20237425; PMCID: PMC3096720.
  103. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28. PMID: 20227509; PMCID: PMC3711411.
  104. Bullinger L, Armstrong SA. HELP for AML: methylation profiling opens new avenues. Cancer Cell. 2010 Jan 19; 17(1):1-3. PMID: 20129241.
    View in: PubMed
  105. Stam RW, Den Boer ML, Schneider P, de Boer J, Hagelstein J, Valsecchi MG, de Lorenzo P, Sallan SE, Brady HJ, Armstrong SA, Pieters R. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2010 Feb 04; 115(5):1018-25. PMID: 19965632.
    View in: PubMed
  106. Kotani A, Ha D, Hsieh J, Rao PK, Schotte D, den Boer ML, Armstrong SA, Lodish HF. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood. 2009 Nov 05; 114(19):4169-78. PMID: 19749093; PMCID: PMC2774553.
  107. Krivtsov AV, Feng Z, Armstrong SA. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:144-9. PMID: 19796242.
    View in: PubMed
  108. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 2009 Jun 05; 4(6):559-67. PMID: 19497284; PMCID: PMC3065323.
  109. Neff T, Armstrong SA. Chromatin maps, histone modifications and leukemia. Leukemia. 2009 Jul; 23(7):1243-51. PMID: 19322211.
    View in: PubMed
  110. Gekas C, Rhodes KE, Gereige LM, Helgadottir H, Ferrari R, Kurdistani SK, Montecino-Rodriguez E, Bassel-Duby R, Olson E, Krivtsov AV, Armstrong S, Orkin SH, Pellegrini M, Mikkola HK. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood. 2009 Apr 09; 113(15):3461-71. PMID: 19211936; PMCID: PMC2945827.
  111. Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2009 Jan; 46(1):33-8. PMID: 19100366; PMCID: PMC4031465.
  112. Krivtsov AV, Wang Y, Feng Z, Armstrong SA. Gene expression profiling of leukemia stem cells. Methods Mol Biol. 2009; 538:231-46. PMID: 19277590; PMCID: PMC3339407.
  113. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009 Mar 12; 113(11):2375-85. PMID: 19056693; PMCID: PMC2656267.
  114. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 04; 14(5):355-68. PMID: 18977325; PMCID: PMC2591932.
  115. Faber J, Gregory RI, Armstrong SA. Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell. 2008 Jun; 13(6):467-9. PMID: 18538729.
    View in: PubMed
  116. Wang Y, Armstrong SA. Cancer: inappropriate expression of stem cell programs? Cell Stem Cell. 2008 Apr 10; 2(4):297-9. PMID: 18397746.
    View in: PubMed
  117. Jones RJ, Armstrong SA. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):12-6. PMID: 18162216.
    View in: PubMed
  118. Jones RJ, Armstrong SA. Cancer Stem Cells in Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2008 Jan; 14(Supplement 1):12-16. PMID: 19122742.
    View in: PubMed
  119. Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9. PMID: 18056841; PMCID: PMC2234061.
  120. Faber J, Armstrong SA. Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. Klin Padiatr. 2007 Nov-Dec; 219(6):306-11. PMID: 18050039.
    View in: PubMed
  121. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007 Nov; 7(11):823-33. PMID: 17957188.
    View in: PubMed
  122. Faber J, Armstrong SA. Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res. 2007 Sep 15; 67(18):8425-8. PMID: 17875678.
    View in: PubMed
  123. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia. 2008 Jan; 22(1):66-77. PMID: 17851551; PMCID: PMC2936245.
  124. Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. Clin Cancer Res. 2007 Jun 15; 13(12):3439-42. PMID: 17575205.
    View in: PubMed
  125. Stubbs MC, Armstrong SA. FLT3 as a therapeutic target in childhood acute leukemia. Curr Drug Targets. 2007 Jun; 8(6):703-14. PMID: 17584026.
    View in: PubMed
  126. Wang Y, Armstrong SA. Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell. 2007 Apr; 11(4):308-9. PMID: 17418407.
    View in: PubMed
  127. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. PMID: 17293865.
    View in: PubMed
  128. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegué E, DePinho RA, Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007 Jan 26; 128(2):325-39. PMID: 17254970.
    View in: PubMed
  129. Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ, Sallan SE, Armstrong SA, Pieters R. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007 May 01; 109(9):3929-35. PMID: 17218380.
    View in: PubMed
  130. Sears C, Armstrong SA. Microarrays to identify new therapeutic strategies for cancer. Adv Cancer Res. 2007; 96:51-74. PMID: 17161676.
    View in: PubMed
  131. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006 Sep 29; 313(5795):1929-35. PMID: 17008526.
    View in: PubMed
  132. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, Golub TR, Armstrong SA. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct; 10(4):331-42. PMID: 17010674.
    View in: PubMed
  133. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22. PMID: 16862118.
    View in: PubMed
  134. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006 May; 9(5):351-65. PMID: 16697956.
    View in: PubMed
  135. Stam RW, den Boer ML, Passier MM, Janka-Schaub GE, Sallan SE, Armstrong SA, Pieters R. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia. 2006 Feb; 20(2):264-71. PMID: 16357833.
    View in: PubMed
  136. Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005 Nov 01; 65(21):10050-8. PMID: 16267031.
    View in: PubMed
  137. Li A, Goldwasser MA, Zhou J, Armstrong SA, Wang H, Dalton V, Fletcher JA, Sallan SE, Silverman LB, Gribben JG. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92. PMID: 16197448.
    View in: PubMed
  138. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6306-15. PMID: 16155013.
    View in: PubMed
  139. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15; 106(10):3377-9. PMID: 16081687; PMCID: PMC1895066.
  140. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005 Oct 01; 106(7):2484-90. PMID: 15956279.
    View in: PubMed
  141. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, Kutok JL, Kogan SC, Zinkel SS, Fisher JK, Hess JL, Golub TR, Armstrong SA, Akashi K, Korsmeyer SJ. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005 Jan 26; 24(2):368-81. PMID: 15635450; PMCID: PMC545811.
  142. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6. PMID: 14670924.
    View in: PubMed
  143. Armstrong SA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol. 2003 Oct; 40(4):268-73. PMID: 14582077.
    View in: PubMed
  144. Armstrong SA, Korsmeyer SJ. Comparison of human genomics and genetic models of cancer to identify novel therapeutic targets. Cell Cycle. 2003 Sep-Oct; 2(5):408-9. PMID: 12963826.
    View in: PubMed
  145. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8. PMID: 12637319.
    View in: PubMed
  146. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83. PMID: 12620411.
    View in: PubMed
  147. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood. 2003 Feb 15; 101(4):1270-6. PMID: 12406912.
    View in: PubMed
  148. Armstrong SA, Hsieh JJ, Korsmeyer SJ. Genomic approaches to the pathogenesis and treatment of acute lymphoblastic leukemias. Curr Opin Hematol. 2002 Jul; 9(4):339-44. PMID: 12042709.
    View in: PubMed
  149. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7. PMID: 11731795.
    View in: PubMed
  150. Dal Cin P, Atkins L, Ford C, Ariyanayagam S, Armstrong SA, George R, Cleary A, Morton CC. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer. 2001 Apr; 30(4):407-9. PMID: 11241794.
    View in: PubMed
  151. Fransz P, Armstrong S, Alonso-Blanco C, Fischer TC, Torres-Ruiz RA, Jones G. Cytogenetics for the model system Arabidopsis thaliana. Plant J. 1998 Mar; 13(6):867-76. PMID: 9681023.
    View in: PubMed
  152. Armstrong SA, Barry DA, Leggett RW, Mueller CR. Casein kinase II-mediated phosphorylation of the C terminus of Sp1 decreases its DNA binding activity. J Biol Chem. 1997 May 23; 272(21):13489-95. PMID: 9153193.
    View in: PubMed
  153. Akimaru H, Chen Y, Dai P, Hou DX, Nonaka M, Smolik SM, Armstrong S, Goodman RH, Ishii S. Drosophila CBP is a co-activator of cubitus interruptus in hedgehog signalling. Nature. 1997 Apr 17; 386(6626):735-8. PMID: 9109493.
    View in: PubMed
  154. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995 May 09; 92(10):4537-41. PMID: 7538675; PMCID: PMC41979.
  155. Andres DA, Seabra MC, Brown MS, Armstrong SA, Smeland TE, Cremers FP, Goldstein JL. cDNA cloning of component A of Rab geranylgeranyl transferase and demonstration of its role as a Rab escort protein. Cell. 1993 Jun 18; 73(6):1091-9. PMID: 8513495.
    View in: PubMed
  156. Armstrong SA, Seabra MC, Südhof TC, Goldstein JL, Brown MS. cDNA cloning and expression of the alpha and beta subunits of rat Rab geranylgeranyl transferase. J Biol Chem. 1993 Jun 05; 268(16):12221-9. PMID: 8505342.
    View in: PubMed
  157. Longmire RL, McMillan R, Yelenosky R, Armstrong S, Lang JE, Craddock CG. In vitro splenic IgG synthesis in Hodgkin's disease. N Engl J Med. 1973 Oct 11; 289(15):763-7. PMID: 4542304.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Armstrong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_